Krystal Biotech, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Krystal Biotech, Inc. on April 29, 2020, regarding executive compensation adjustments approved by the Compensation Committee. The filing addresses 2019 cash bonus awards and a 2020 target bonus adjustment for the Company's CEO and COO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- CEO (Krish Krishnan) 2019 Cash Bonus: $254,153 (105% of target).
- COO (Suma Krishnan) 2019 Cash Bonus: $140,054 (105% of target).
- CEO Total 2019 Compensation (Updated): $619,878.
- COO Total 2019 Compensation (Updated): $495,444.
Material Changes
The primary material change is the update to the Summary Compensation Table previously disclosed in the April 14, 2020 Proxy Statement. The prior filing did not reflect the 2019 bonus awards as they were undetermined at that time. Additionally, the COO's target bonus for 2020 was increased from 35% to 50% of her base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It is a disclosure of specific compensatory arrangements.
Key Facts for Investor Verification
- Verify the updated total compensation figures for the CEO and COO in the Company's definitive proxy statement or subsequent filings.
- Confirm the 2020 target bonus percentage for the COO is now 50% of base salary.
- Note that the 2019 bonus payout rate was 105% of target for both executives.